Adimab and Mersana link to provide antibody-drug conjugate tools to partners
This article was originally published in Scrip
Executive Summary
Adimab and Mersana Therapeutics announced a partnership on 1 August to offer integrated antibody discovery and antibody-drug conjugate (ADC) technologies to pharmaceutical partners. No financial details were disclosed.